Linde PLC

Little Green Pharma’s 2026 results reveal a shift to a modest loss but rising revenue, EBITDA, and cash flow, underpinned by European expansion, vertical integration, and a commitment to sustainability and regulatory influence in the medicinal canna…

Explore how Linde PLC’s insider share purchase and RSU strategy reveal executive ownership trends, rebranding impacts, and future governance risks.

Executive buys, Argus upgrades, and Soros adds shares show growing confidence in Linde PLC’s hydrogen‑driven growth and potential upside beyond the current high‑five‑hundreds.

Explore Linde PLC’s recent Form 144 insider sales—small, compliant trades that reveal routine liquidity management and shed light on governance, ESG focus, and market dynamics.

Helium market tightening: Linde PLC’s strategic positioning and analyst‑boosted upside keep it poised for growth amid rising demand from semiconductors, medical tech, aerospace, and advanced manufacturing.

Linde plc’s Kangankunde Rare Earths Project in Malawi hits key milestones and remains fully funded, while a new SEC shelf registration boosts capital flexibility and analyst confidence.

Explore how Linde plc’s 23‑year sustainability streak and new capital‑raising flexibility are reshaping its ESG profile, emissions impact, and market resilience.

Explore Linde PLC’s recent market moves, supply‑chain challenges, digital‑transformation plans, and hydrogen‑driven growth potential—insights for investors and industry experts.

Explore Linde PLC’s Q1 2026 earnings: 10% EPS rise, robust revenue, strategic acquisitions, and dividend growth, positioning it as a top performer in industrial gases and chemicals.

Check out Linde plc’s Q1 2026 results: steady sales, robust margins, and a green‑energy push that boosts earnings and shareholder returns.